## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.0% below STRENGTH zone (3.0-6.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($214.86)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Goldman Sachs initiates Danaher stock with Buy rating on bioprocessing strength**
- Source: Investing.com India | 20251209T082409 | Bullish | Relevance: 100%
-  Goldman Sachs has initiated coverage on Danaher (NYSE:DHR) with a Buy rating and a $265.00 price target, citing the company's robust $6 billion bioprocessing franchise and its growth potential. The firm believes that easing equipment demand overhangs and the trend towards CDMO outsourcing will drive improved bioprocessing equipment placements. This positive outlook is further supported by Danaher's strong Q3 2025 earnings and a recent credit rating upgrade from Moody's.

**2. Cresset Asset Management LLC Has $6.05 Million Stock Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251207T090809 | Somewhat-Bullish | Relevance: 100%
-  Cresset Asset Management LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 27.2% in Q2, now holding 30,592 shares valued at approximately $6.05 million. This comes as other major institutions like Vanguard and Norges Bank have significantly increased their positions, with institutional investors now owning 79.05% of DHR stock. Danaher also beat recent earnings estimates, reporting $1.89 EPS and $6.05 billion in revenue, and maintains a "Moderate Buy" consensus rating among analysts with an average target price of $245.75.

**3. Ossiam Has $28.59 Million Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T115110 | Bullish | Relevance: 99%
-  Ossiam significantly increased its stake in Danaher Corporation by 716.7% in Q2, bringing its total holdings to 144,744 shares valued at $28.59 million. Despite recent insider sales totaling over $6.6 million, Wall Street analysts maintain a "Moderate Buy" consensus rating for Danaher, with an average price target of $245.75, following its beat on quarterly EPS expectations. The company also announced a quarterly dividend of $0.32 per share, yielding 0.6% annually.

**4. Natixis Increases Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T124105 | Somewhat-Bullish | Relevance: 99%
- Natixis significantly increased its stake in Danaher Corporation by 59% in Q2, bringing its total holdings to 166,877 shares valued at approximately $32.97 million. Danaher reported strong Q2 earnings, beating analyst expectations with an EPS of $1.89 and revenue of $6.05 billion. Despite some insider selling, institutional ownership remains high at 79.05%, and analysts maintain a "Moderate Buy" consensus with an average target price of $245.75.

**5. Temasek Holdings Private Ltd Grows Position in Danaher Corporation $DHR**
- Source: MarketBeat | 20251208T123505 | Somewhat-Bullish | Relevance: 98%
-  Temasek Holdings Private Ltd increased its stake in Danaher Corporation by 69.1% during the second quarter, now owning 109,900 shares valued at $21.71 million. Several other institutional investors also adjusted their positions, and analysts have issued "buy" and "overweight" ratings for Danaher. The article also details recent insider stock sales, dividend announcements, and the company's financial performance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.7x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $160.7B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.7 |
| Current P/E | 29.1 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -2.0% (minimal 5-day change). Below STRENGTH zone by 5.0pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-0.51), momentum weakening. RSI neutral at 55.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.05% (CS: 34) | Weak |
| RSI_14 | 54.7 | Neutral |
| MACD Histogram | -0.51 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.105x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $224.48
- **Stop Loss:** $214.86 (4.3% risk)
- **Target:** $234.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 51
- **Position Value:** $11,448.48
- **Portfolio %:** 11.45%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*